Ronald M. Loeb Center for Alzheimer’s Disease

About Us

The Ronald M. Loeb Center for Alzheimer's Disease contributes significantly to the Icahn School of Medicine at Mount Sinai’s powerful history of major breakthroughs against this devastating illness. We support state-of-the-art research, in collaboration with compassionate clinical care, to fuel the development of transformative new drugs and therapeutics. By bringing the newest treatments from bench to bedside, and by providing a wealth of insight and information on coping with Alzheimer's disease, we offer new hope for patients and their loved ones.

Building upon the growing evidence that Alzheimer's disease is driven not by single, discrete genes but by the subtle interactions among a diffuse network of genes, clinicians and scientists at the Loeb Center are pioneering new ways to diagnose, prevent, and treat the disease. Our work will be supercharged by some of the most advanced research resources in academic medicine, including the largest supercomputer ever built specifically for genomics investigation and a stem cell engineering program that will enable researchers to grow neurons and other brain cells for further study. These efforts support a robust clinical trial program, sponsored by Mount Sinai's NIH-supported Alzheimer's Disease Research Center. This Center maintains one of the most active sites among the national Alzheimer's Disease Cooperative Study network and includes 400 patients recruited over the past five years. We also partner with The Center for Cognitive Health, a multi-disciplinary team of neurologists, psychiatrists, neuropsychologists, neuroscientists, and patient care managers who use a fully integrated approach to brain and behavior to provide for comprehensive diagnosis and treatment of a wide range of cognitive disorders.

The Loeb Center will enable new discoveries and ultimately make a meaningful difference in the diagnosis and treatment of Alzheimer's disease–affecting countless patients and their families who live with this terrible disease every day.

Ever since Kenneth L. Davis, MD, CEO and President of the Mount Sinai Health System, first described the cholinomimetic therapy that has become the basis for today's standard of Alzheimer's disease care 35 years ago, the Mount Sinai Health System has been at the forefront of Alzheimer's research and clinical care. (Today, Dr. Davis is President and Chief Executive Officer of the Mount Sinai Health System). We were one of the first five medical centers to be designated an Alzheimer's Disease Research Center by the National Institutes of Health. Our numerous contributions to the field include research that led to four of the first five FDA-approved drugs; the development of the most widely used Alzheimer's disease assessment tool worldwide; and crucial descriptions of the biology of the amyloid plaque protein.

Donate to Research